This study is designed to investigate the pharmacokinetic drug interaction between Udenafil and Dapoxetine in healthy male subjects. The clinical trial aims to evaluate how these drugs influence each other’s absorption, distribution, metabolism, and excretion in the body. Participants selected for this study must be healthy males, aged between 18 and 50 years, without any significant health issues that could interfere with the trial results. The objective is to gather data that could improve treatment protocols for erectile dysfunction and premature ejaculation by understanding how these two medications work together.
The trial employs a randomized, open-label, crossover design, which means participants will receive both drugs in different sequences to compare their pharmacokinetic profiles. The study includes multiple phases, beginning with a washout period to ensure no drug interference. Participants will receive specific doses of Udenafil and Dapoxetine, followed by a series of blood tests to measure drug levels over time. This approach will help identify any changes in drug behavior when taken together, providing valuable information for optimizing dosing strategies and minimizing potential side effects.
For those interested in participating or learning more about the trial, detailed contact information and location details are available on the official website. This trial is being conducted in Denmark, and all inquiries should be directed to the appropriate contact points listed there. Prospective participants should note the importance of adhering to the study requirements and maintaining communication with the research team to ensure accurate data collection and a successful trial experience.